These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8422666)

  • 1. Characterization of the exogenous interleukin-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.
    Rubin M; Mokyr MB
    Cancer Immunol Immunother; 1993; 36(1):37-44. PubMed ID: 8422666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.
    Mokyr MB; Bartik MM; Ahn MC
    Cancer Res; 1989 Feb; 49(4):870-6. PubMed ID: 2783557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.
    Bartik MM; Baumgartel-Scofield BA; Mokyr MB
    Cancer Immunol Immunother; 1991; 34(2):79-89. PubMed ID: 1760820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy.
    Bartik MM; Ahn MC; Baumgartel BA; Hendricks RL; Mokyr MB
    Cancer Immunol Immunother; 1990; 32(3):143-53. PubMed ID: 2289208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers.
    Weiskirch LM; Baumgartel BA; Barker E; Mokyr MB
    Cancer Immunol Immunother; 1991; 32(6):353-63. PubMed ID: 1901031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
    Bartik MM; Takesue BY; Mokyr MB
    Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens.
    Takesue BY; Bartik MM; Mokyr MB
    Int J Immunopharmacol; 1987; 9(6):705-17. PubMed ID: 2891627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.
    Gorelik L; Prokhorova A; Mokyr MB
    Cancer Immunol Immunother; 1994 Aug; 39(2):117-26. PubMed ID: 8044831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.
    Gorelik L; Rubin M; Prokhorova A; Mokyr MB
    J Immunol; 1995 Apr; 154(8):3941-51. PubMed ID: 7706732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
    Weiskirch LM; Mokyr MB
    Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
    Barker E; Wise JA; Dray S; Mokyr MB
    Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.
    Mokyr MB; Barker E; Weiskirch LM; Takesue BY; Pyle JM
    Cancer Res; 1989 Aug; 49(16):4597-606. PubMed ID: 2568174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
    Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA
    J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
    Mokyr MB; Kalinichenko TV; Gorelik L; Bluestone JA
    J Immunol; 1998 Feb; 160(4):1866-74. PubMed ID: 9469448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.
    Takesue BY; Pyle JM; Mokyr MB
    Cancer Res; 1990 Dec; 50(23):7641-9. PubMed ID: 2123740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma.
    Cook-Mills JM; Mokyr MB; Cohen RL; Perlman RL; Chambers DA
    Cancer Immunol Immunother; 1995 Feb; 40(2):79-87. PubMed ID: 7882386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.
    Weiskirch LM; Bar-Dagan Y; Mokyr MB
    Cancer Immunol Immunother; 1994 Apr; 38(4):215-24. PubMed ID: 8168116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E; Mokyr MB
    Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.
    Mokyr MB; Barker E
    Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.
    Barker E; Mokyr MB
    Cancer Immunol Immunother; 1987; 25(3):215-24. PubMed ID: 3677124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.